XML 47 R37.htm IDEA: XBRL DOCUMENT v3.23.1
Collaborative Arrangements - Financial Information (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Sales $ 14,487 $ 15,901  
Cost of sales 3,926 5,380  
Selling, general and administrative 2,479 2,323  
Research and development 4,276 2,576  
Payables included in Accrued and other liabilities 23,131   $ 24,239
Amortization 543 699  
Alliance revenue - Lenvima      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Amortization 72    
Other current assets | AstraZeneca | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Receivables included in Other current assets 303   303
Other current assets | Eisai | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Receivables included in Other current assets 244   214
Other current assets | Bayer AG | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Receivables included in Other current assets 142   143
Accounts Payable and Accrued Liabilities | AstraZeneca | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Payables included in Accrued and other liabilities 21   123
Accounts Payable and Accrued Liabilities | Eisai | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Payables included in Accrued and other liabilities 125   0
Accounts Payable and Accrued Liabilities | Bayer AG | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Payables included in Accrued and other liabilities 68   80
Accounts Payable and Accrued Liabilities | Ridgeback Biotherapeutics LP | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Payables included in Accrued and other liabilities 191   348
Other Noncurrent Liabilities | AstraZeneca | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Payables included in Other Noncurrent Liabilities 600   $ 600
Revenue | AstraZeneca | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Alliance revenue - profit sharing 298 275  
Revenue | AstraZeneca | Collaborative Arrangement | Alliance revenue - Lynparza      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Alliance revenue - profit sharing 275 266  
Revenue | AstraZeneca | Collaborative Arrangement | Alliance revenue - Koselugo      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Alliance revenue - profit sharing 23 9  
Revenue | Eisai | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Alliance revenue - profit sharing 232 227  
Revenue | Bayer AG | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Alliance revenue - profit sharing 99 72  
Sales 165 136  
Revenue | Bayer AG | Collaborative Arrangement | Adempas      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Net sales by Merck 59 61  
Revenue | Bayer AG | Collaborative Arrangement | Verquvo      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Net sales by Merck 7 3  
Revenue | Ridgeback Biotherapeutics LP | Collaborative Arrangement | Lagevrio      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Sales 392 3,247  
Cost of sales | AstraZeneca | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Cost of sales 70 299  
Amortization of intangible assets 250    
Cost of sales | Eisai | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Cost of sales 126 53  
Cost of sales | Bayer AG | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Cost of sales 57 50  
Cost of sales | Ridgeback Biotherapeutics LP | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Cost of sales 221 1,726  
Selling, general and administrative | AstraZeneca | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Selling, general and administrative 47 44  
Selling, general and administrative | Eisai | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Selling, general and administrative 51 31  
Selling, general and administrative | Bayer AG | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Selling, general and administrative 33 23  
Selling, general and administrative | Ridgeback Biotherapeutics LP | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Selling, general and administrative 27 35  
Research and development | AstraZeneca | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Research and development 21 26  
Research and development | Eisai | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Research and development 39 57  
Research and development | Bayer AG | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Research and development 25 17  
Research and development | Ridgeback Biotherapeutics LP | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Research and development $ 16 $ 25